What is PrismRA?
PrismRA® is the first-of-its-kind molecular signature test designed to help your provider find the right treatment for you as early as possible. All it takes is a blood draw that can be done in your doctor’s office.
The test helps decode your molecular signature to predict whether you are unlikely to respond adequately to a common category of RA treatment called TNF inhibitors (TNFi).
Examples of TNFi therapies include Cimzia®, Enbrel®, Humira®,
Remicade® and Simponi®.
How PrismRA works
PrismRA can help your doctor provide earlier access to alternative approved therapies if your molecular signature shows that you are unlikely to respond adequately to TNFi therapies. The blood test analyzes 23 biological features in order to decode your molecular signature and predict your likelihood of inadequate response to TNFi therapies with 90% accuracy1.
Now, your provider can make more informed treatment decisions by selecting a therapy based on your individual information, improving your quality of life and avoiding irreversible joint damage.
What is a molecular signature and how can it predict treatment response?
Like fingerprints, molecular signatures are unique. They combine a set of personalized biological features, including RNA and proteins, to determine an individual’s genetic makeup. Molecular signatures can even be used to predict how a person will experience their disease and how they will respond to different targeted therapies, like TNFi therapies. When patients fail to respond to a TNFi therapy, it is likely because his or her RA symptoms are not sufficiently caused by the same protein that TNFI therapies target.